Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pharmaceutical Pipeline Guide, H2, 2017

Albany, New York, July 31, 2017: Market Research Hub’s latest Pharmaceutical and Healthcare disease pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Review, H2 2017, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline landscape. Coronary artery disease (CAD) is the most common type of heart disease. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls.

Request Free Sample Report @

This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can’t get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the hearts’ blood supply, causing permanent heart damage. The most common symptom of coronary artery disease is angina, or chest pain. Other symptoms include shortness of breath, palpitations, a faster heartbeat, weakness or dizziness, nausea and sweating.

Report Highlights

Market Research Hub’s Pharmaceutical and Healthcare latest pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 4, 15, 8, 1, 18 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Market Research Hubs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


– The pipeline guide provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).
– The pipeline guide reviews pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular)

Browse Full Report with TOC @

Reasons to Buy: 

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content:

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Overview 8
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 18
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Therapeutics Assessment 19
Assessment by Target 19
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Companies Involved in Therapeutics Development 28
Amarantus Bioscience Holdings Inc 28
AnGes MG Inc 28
Angionetics Inc 29
Ascendia Pharmaceuticals LLC 29
AstraZeneca Plc 30
Athera Biotechnologies AB 30
Bayer AG 31
Biscayne Pharmaceuticals Inc 31
Capricor Therapeutics Inc 32
CardioVascular BioTherapeutics Inc 32
CSL Ltd 33
Gilead Sciences Inc 33
Human Stem Cells Institute 34
Idorsia Ltd 34
Juventas Therapeutics Inc 35
Lee’s Pharmaceutical Holdings Ltd 35
LipimetiX Development Inc 36
Livzon Pharmaceutical Group Inc 36
Lonestar Heart Inc 37
MedImmune LLC 37
Merck & Co Inc 38
Nuo Therapeutics Inc 39
Pfizer Inc 39
Proteon Therapeutics Inc 40
Resverlogix Corp 40
Tasly Pharmaceutical Group Co Ltd 40
The Medicines Company 41
Verseon Corp 42
VESSL Therapeutics Ltd 42

Make an Enquiry @

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of Research Reports and analysis. MRH’s expansive collection of pharmaceutical market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,
Albany, NY 12207,
United States

Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074


Designed by
Powered by
%d bloggers like this: